pyrroles has been researched along with Bright Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azizi, M; Bobrie, G; Bouché, O; Deray, G; des Guetz, G; Halimi, JM; Lecomte, T; Levy, B; Mourad, JJ; Nochy, D; Oudard, S; Rieu, P; Sahali, D | 1 |
| Holdsworth, SR; Jones, LK; Kitching, AR; Phoon, RK | 1 |
| Eller, K; Eller, P; Mayer, G; Patsch, JR; Reinstadler, SJ; Rosenkranz, AR; Tagwerker, A; Wolf, AM | 1 |
| Al Nuaimi, H; Al-Ani, B; Savage, C | 1 |
| Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J | 1 |
| Arisz, L; Kastelein, JJ; Koopman, MG; Ozsoy, RC | 1 |
| Lavoie, S; Lipson, J; Zimmerman, D | 1 |
| Gumpel, JM; Prouse, PJ; Wilson, AP | 1 |
8 other study(ies) available for pyrroles and Bright Disease
| Article | Year |
|---|---|
[Vascular and renal effects of anti-angiogenic therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Glomerular Filtration Rate; Glomerulonephritis; Humans; Indoles; Kidney; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Atorvastatin enhances humoral immune responses but does not alter renal injury in experimental crescentic glomerulonephritis.
Topics: Animals; Atorvastatin; CD4-Positive T-Lymphocytes; Dose-Response Relationship, Drug; Glomerulonephritis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Humoral; Kidney; Male; Mice; Mice, Inbred C57BL; Pyrroles | 2009 |
Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis.
Topics: Animals; Atorvastatin; CD4-Positive T-Lymphocytes; Glomerular Basement Membrane; Glomerulonephritis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-10; Kidney Glomerulus; Male; Mice; Mice, Inbred C57BL; Pyrroles; T-Lymphocyte Subsets; Th1 Cells | 2010 |
The beneficial effects of statin therapy may not apply to all forms of crescentic glomerulonephritis.
Topics: Animals; Atorvastatin; Disease Models, Animal; Glomerulonephritis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Rats; Rats, Inbred WKY; Simvastatin | 2011 |
[Renal tolerance of targeted therapies].
Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2012 |
The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol; Chronic Disease; Creatinine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerulonephritis; Heptanoic Acids; Humans; Insulin; Insulin, Long-Acting; Insulin, Regular, Human; Lipoproteins; Male; Middle Aged; Proteinuria; Pyrroles; Retrospective Studies; Serum Albumin; Serum Albumin, Human; Time Factors; Treatment Outcome | 2005 |
Gabapentin-induced myopathy in 2 patients on short daily hemodialysis.
Topics: Adult; Amines; Anticonvulsants; Atorvastatin; Calcium Channels; Comorbidity; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Glomerulonephritis; Glomerulonephritis, Membranoproliferative; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Neuromuscular Diseases; Peritoneal Dialysis; Physical Exertion; Postoperative Complications; Pyrroles; Recurrence; Renal Dialysis; Restless Legs Syndrome | 2005 |
Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Auranofin; Aurothioglucose; Female; Glomerulonephritis; Gold; Humans; Middle Aged; Proteinuria; Pyrroles; Tolmetin | 1984 |